Gastrin secretion in normal subjects and diabetes patients is inhibited by glucagon-like peptide 1: a role in the gastric side effects of GLP-1-derived drugs?

References

• Rehfeld JF. Gastrointestinal hormone research – with a Scandinavian annotation. Scand J Gastroenterol. 2015;50(6):668–679.
   PubMed Web of Science ®Google Scholar
• Rehfeld JF. Gastrointestinal hormones and their targets. Adv Exp Med Biol. 2014;817:157–175.
   PubMed Web of Science ®Google Scholar
• Larsson LI, Goltermann N, de Magistris L, et al. Somatostatin cell processes as pathways for paracrine secretion. Science. 1979;205(4413):1393–1395.
   PubMed Web of Science ®Google Scholar
• Kumar U, Grant M. Somatostatin and somatostatin receptors. Results Probl Cell Differ. 2010;50:137–184.
   PubMedGoogle Scholar
• Chen D, Zhao CM, Håkanson R, et al. Altered control of gastric acid secretion in gastrin-cholecystokinin double mutant mice. Gastroenterology. 2004;126(2):476–487.
   PubMed Web of Science ®Google Scholar
• Cao Y, Cao X, Liu XM. Expression of cholecystokinin 2-receptor in rat and human L cells and the stimulation of glucagon-like peptide-1 secretion by gastrin treatment. Acta Histochem. 2015;117(2):205–210.
   PubMed Web of Science ®Google Scholar
• Cooper CW, Schwesinger WH, Ontjes DA, et al. Stimulation of secretion of pig-thyrocacitonin by gastrin and related hormonal peptides. Endocrinology. 1972;91(4):1079–1089.
   PubMed Web of Science ®Google Scholar
• Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3(3):153–165.
   PubMed Web of Science ®Google Scholar
• Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409–1439.
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. . 2015;373(1):11–22.
   PubMed Web of Science ®Google Scholar
• Davies MJ, Bergenstal R, Bode B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA. 2015;314(7):687–699.
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322.
   PubMed Web of Science ®Google Scholar
• Smits MM, Tonneijck L, Muskiet MH, et al. Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients. Diabetes Obes Metab. 2016;18(12):1217–1225.
   PubMed Web of Science ®Google Scholar
• Li M, Yang Y, Jiang D, et al. Efficacy and safety of liraglutide versus sitagliptin both in combination with metformin in patients with type 2 diabetes: a systematic review and meta-analysis. Medicine. 2017;96(39):e8161.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Buse JB, Azeem R, et al. Efficacy and safety of ITCA 650, a novel drug-device GLP-1 receptor agonist, in type 2 diabetes uncontrolled with oral antidiabetes drugs: the FREEDOM-1 trial. Dia Care. 2018;41(2):333–340.
   PubMed Web of Science ®Google Scholar
• Waldrop G, Zhong J, Peters M, et al. Incretin-based therapy in type 2 diabetes: an evidence based systematic review and meta-analysis. J Diabetes Complications. 2018;32(1):113–122.
   PubMed Web of Science ®Google Scholar
• Eissele R, Koop H, Arnold R. Effect of glucagon-like peptide-1 on gastric somatostatin and gastrin secretion in the rat. Scand J Gastroenterol. 1990;25(5):449–454.
   PubMed Web of Science ®Google Scholar
• Asmar M, Bache M, Knop FK, et al. Do the actions of glucagon-like peptide-1 on gastric emptying, appetite, and food intake involve release of amylin in humans? J Clin Endocrinol Metab. 2010;95(5):2367–2375.
   PubMed Web of Science ®Google Scholar
• Rehfeld JF, Knop FK, Asmar A, et al. Cholecystokinin secretion is suppressed by glucagon-like peptide-1: clue to the mechanism of the adverse gallbladder events of GLP-1-derived drugs. Scand J Gastroenterol. 2018;53(12):1429–1432.
   PubMed Web of Science ®Google Scholar
• Rehfeld JF, Stadil F, Rubin B. Production and evaluation of antibodies for the radioimmunoassay of gastrin. Scand J Clin Lab Invest. 1972;30(2):221–232.
   PubMed Web of Science ®Google Scholar
• Stadil F, Rehfeld JF. Determination of gastrin in serum: an evaluation of the reliability of a radioimmunoassay. Scand J Gastroenterol. 1973;8(2):101–112.
   PubMed Web of Science ®Google Scholar
• Gregory RA, Tracy HJ. The constitution and properties of two gastrins extracted from hog antral mucosa. Gut. 1964;5(2):103–117.
   PubMed Web of Science ®Google Scholar
• Friis-Hansen L, Sundler F, Li Y, et al. Impaired gastric acid secretion in gastrin-deficient mice. Am H Physiol. 1998;274:G561–G568.
   PubMed Web of Science ®Google Scholar
• Friis-Hansen L, Rieneck K, Nilsson HO, et al. Gastric inflammation, metaplasia, and tumor development in gastrin-deficient mice. Gastroenterology. 2006;131:246–258.
   PubMed Web of Science ®Google Scholar
• Berna MJ, Hoffmann KM, Serrano J, et al. Serum gastrin in Zollinger-Ellison syndrome: I. Prosepective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Medicine (Baltimore). 2006;85(6):295–330.
   PubMed Web of Science ®Google Scholar
• Waldum HL, Hausø Ø, Sørdal ØF, et al. Gastrin may mediate the carcinogenic effect of Helicobacter pylori infection of the stomach. Dig Dis Sci. 2015;60(6):1522–1527.
   PubMed Web of Science ®Google Scholar
• Jiann CS, Lange OJ, Viset T, et al. Gastric neuroendocrine carcinoma after long-term use of proton pump inhibitor. Scand J Gastroenterol. 2012;47:64–67.
   PubMed Web of Science ®Google Scholar
• Kopin AS, McBride EW, Schaffer K, et al. CCK receptor polymorphisms: an illustration of emerging themes in pharmacogenomics. Trends Pharmacol Sci. 2000;21(9):346–553.
   PubMed Web of Science ®Google Scholar
• Reubi JC, Waser B, Gugger M, et al. Distribution of CCK1 and CCK2 receptors in normal and diseased human pancreatic tissue. Gastroenterology. 2003;125(1):98–106.
   PubMed Web of Science ®Google Scholar
• Konno K, Takahashi-Iwanaga H, Uchigashima M, et al. Cellular and subcellular localization of cholecystokinin (CCK)-1 receptors in the pancreas, gallbladder, and stomach of mice. Histochem Cell Biol. 2015;143(3):301–312.
   PubMed Web of Science ®Google Scholar
• Rehfeld JF. Why cholecystokinin and gastrin are also incretins. Cardiovasc Endocrinol. 2016;5(3):99–101.
   Google Scholar
• Rehfeld JF. CCK, gastrin and diabetes mellitus. Biomarkers Med. 2016;10(11):1125–1127.
   PubMed Web of Science ®Google Scholar
• Suarez-Pinzon WL, Power RF, Yan Y, et al. Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice. Diabetes. 2008;57(12):3281–3288.
   PubMed Web of Science ®Google Scholar
• Fosgerau K, Jessen L, Lind Tolborg J, et al. The novel GLP-1-gastrin dual agonist, ZP3022, increases β-cell mass and prevents diabetes in db/db mice. Diabetes Obes Metab. 2013;15(1):62–71.
   PubMed Web of Science ®Google Scholar
• Keller J, Trautmann ME, Haber H, et al. Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects. Regul Pept. 2012;179(1–3):77–83.
   PubMedGoogle Scholar
• Halawi H, Khemani D, Eckert D, et al. Effects of liraglutide on weight, satiation and gastric functions in obesity: a randomized, placebo-controlled pilot trial. Lancet Gastroenterol Hepatol. 2017;2:890–899.
   PubMed Web of Science ®Google Scholar
• Ørskov C, Holst JJ, Nielsen OV. Effect of truncated glucagon-like peptide-1 [proglucagon-(78-1079 amide] on endocrine secretion from pig pancreas, antrum and non-antral stomach. Endocrinology. 1988;123(4):2009–2013.
   PubMed Web of Science ®Google Scholar